Lord, Abbett & Co
DAWN

Lord, Abbett & Co’s Day One Biopharmaceuticals DAWN Stock Holding History

Lord, Abbett & Co’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-402,440
Closed -$5.38M – 545
2023
Q1 		$5.38M Sell
402,440
-103,738
-20% -$2.03M 0.02% 470
2022
Q4 		$10.9M Buy
506,178
+1,927
+0.4% +$39.5K 0.04% 415
2022
Q3 		$10.1M Buy
+504,251
New +$10.7M 0.04% 406

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

Lord, Abbett & Co's DAWN Position: Q2 2023 in Review

Lord, Abbett & Co sold out of Day One Biopharmaceuticals (DAWN) in Q2 2023, closing a stake of 402,440 shares — an estimated $5.38M sold.

Lord, Abbett & Co first reported a position in DAWN in Q3 2022 and held it in 3 quarters. The position peaked at $10.9M in Q4 2022. 140 funds tracked by Wall St. Rank hold DAWN as of Q2 2023.

  • Lord, Abbett & Co reported no remaining Day One Biopharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 402,440 Day One Biopharmaceuticals shares in Q2 2023, an estimated $5.38M.
  • Lord, Abbett & Co first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Lord, Abbett & Co's Day One Biopharmaceuticals position peaked at $10.9M in Q4 2022.
  • 140 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2023.

Based on Lord, Abbett & Co's 13F filing for Q2 2023, filed 14 Aug 2023.